CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Furosemide

呋塞米 杂质对照品Furosemide Impurities

EP43 个杂质条目43 impurity entries

本页汇总 呋塞米 的 43 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 43 impurity reference standards of Furosemide with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 呋塞米(Furosemide)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSimultaneous Development and Validation of an HPLC Method for the Determination of Furosemide and Its Degraded Compound in Pediatric Extemporaneous Furosemide Oral Solution
    Molecules (Basel, Switzerland) · 2025 · Srejomthong K et al.  ·  PMID 41097451  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and validation of a stability-indicating HPLC assay method for simultaneous determination of spironolactone and furosemide in tablet formulation
    Journal of chromatographic science · 2012 · Ram VR et al.  ·  PMID 22641089  ·  DOI
  3. 杂质研究Impurity studiesIsolation and Characterization of an Unknown Process-Related Impurity in Furosemide and Validation of a New HPLC Method
    Molecules (Basel, Switzerland) · 2023 · Xu A et al.  ·  PMID 36903659  ·  DOI
  4. 分析方法Analytical MethodsHigh-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection
    Biomedical chromatography : BMC · 2006 · Chawla S et al.  ·  PMID 16161180  ·  DOI
  5. 分析方法Analytical MethodsDetermination of furosemide in pharmaceutical formulations by diffuse reflectance spectroscopy
    Talanta · 2004 · Gotardo MA et al.  ·  PMID 18969612  ·  DOI

呋塞米 —— 原料药与杂质对照品Furosemide — drug substance & impurities

共 43 个条目(含原料药本体)43 items incl. the drug substance
Furosemide Impurity 1 (Furosemide EP Impurity A) structure
EPA
呋塞米杂质1 (呋塞米EP杂质A)Furosemide Impurity 1 (Furosemide EP Impurity A)
Furosemide Impurity 1 (Furosemide EP Impurity A)
CAS No.4818-59-1
Chemical FormulaC12H11ClN2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 2 (Furosemide EP Impurity B) structure
EPB
呋塞米杂质2 (呋塞米EP杂质B)Furosemide Impurity 2 (Furosemide EP Impurity B)
Furosemide Impurity 2 (Furosemide EP Impurity B)
CAS No.2736-23-4
Chemical FormulaC7H5Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 3 (Furosemide EP Impurity C) structure
EPC
呋塞米杂质3 (呋塞米EP杂质C)Furosemide Impurity 3 (Furosemide EP Impurity C)
Furosemide Impurity 3 (Furosemide EP Impurity C)
CAS No.3086-91-7
Chemical FormulaC7H7ClN2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 4 (Furosemide EP Impurity D) structure
EPD
呋塞米杂质4 (呋塞米EP杂质D)Furosemide Impurity 4 (Furosemide EP Impurity D)
Furosemide Impurity 4 (Furosemide EP Impurity D)
CAS No.5046-19-5
Chemical FormulaC17H17N3O6S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 5 (Furosemide EP Impurity E) structure
EPE
呋塞米杂质5 (呋塞米EP杂质E)Furosemide Impurity 5 (Furosemide EP Impurity E)
Furosemide Impurity 5 (Furosemide EP Impurity E)
CAS No.50-84-0
Chemical FormulaC7H4Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 6 (Furosemide EP Impurity F) (Mixture of Enantiomers) structure
EPF
呋塞米杂质6 (呋塞米EP杂质F) (对映异构体混合物)Furosemide Impurity 6 (Furosemide EP Impurity F) (Mixture of Enantiomers)
Furosemide Impurity 6 (Furosemide EP Impurity F) (Mixture of Enantiomers)
CAS No.4793-38-8
Chemical FormulaC12H15ClN2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 7 structure
7
呋塞米杂质7Furosemide Impurity 7
Furosemide Impurity 7
CAS No.4753-68-8
Chemical FormulaC5H7NO·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 8 structure
8
呋塞米杂质8Furosemide Impurity 8
Furosemide Impurity 8
CAS No.41332-59-6
Chemical FormulaC7H4Cl2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 10 structure
10
呋塞米杂质10Furosemide Impurity 10
Furosemide Impurity 10
CAS No.2309465-74-3
Chemical FormulaC17H16N2O7S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 11 structure
11
呋塞米杂质11Furosemide Impurity 11
Furosemide Impurity 11
CAS No.518336-22-6
Chemical FormulaC12H10ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 12 structure
12
呋塞米杂质12Furosemide Impurity 12
Furosemide Impurity 12
CAS No.74793-12-7
Chemical FormulaC12H10ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 15(Furosemide Acyl Glucuronide) structure
15
呋塞米杂质15(呋塞米酰基葡糖苷酸)Furosemide Impurity 15(Furosemide Acyl Glucuronide)
Furosemide Impurity 15(Furosemide Acyl Glucuronide)
CAS No.72967-59-0
Chemical FormulaC18H19ClN2O11S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 16 structure
16
呋塞米杂质16Furosemide Impurity 16
Furosemide Impurity 16
CAS No.133989-65-8
Chemical FormulaC12H12N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 17 structure
17
呋塞米杂质17Furosemide Impurity 17
Furosemide Impurity 17
CAS No.4793-47-9
Chemical FormulaC12H12ClN3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 18 structure
18
呋塞米杂质18Furosemide Impurity 18
Furosemide Impurity 18
CAS No.62574-66-7
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 21 structure
21
呋塞米杂质21Furosemide Impurity 21
Furosemide Impurity 21
CAS No.50-75-9
Chemical FormulaC7H3Cl3O2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 22 structure
22
呋塞米杂质22Furosemide Impurity 22
Furosemide Impurity 22
CAS No.2309462-39-1
Chemical FormulaC12H10ClNO6S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 23 structure
23
呋塞米杂质23Furosemide Impurity 23
Furosemide Impurity 23
CAS No.18240-50-1
Chemical FormulaC10H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 24 structure
24
呋塞米杂质24Furosemide Impurity 24
Furosemide Impurity 24
CAS No.2760-11-4
Chemical FormulaC7H6Cl2N2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 26 structure
26
呋塞米杂质26Furosemide Impurity 26
Furosemide Impurity 26
CAS No.1438-94-4
Chemical FormulaC9H9NO
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 27 structure
27
呋塞米杂质27Furosemide Impurity 27
Furosemide Impurity 27
CAS No.3740-18-9
Chemical FormulaC7H3Cl3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 29 structure
29
呋塞米杂质29Furosemide Impurity 29
Furosemide Impurity 29
CAS No.76852-02-3
Chemical FormulaC11H11ClN2O3S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 34 structure
34
呋塞米杂质34Furosemide Impurity 34
Furosemide Impurity 34
CAS No.1235406-09-3
Chemical FormulaC24H20F3N7O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 38 structure
38
呋塞米杂质38Furosemide Impurity 38
Furosemide Impurity 38
CAS No.62971-57-7
Chemical FormulaC7H5Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 39 structure
39
呋塞米杂质39Furosemide Impurity 39
Furosemide Impurity 39
CAS No.50-30-6
Chemical FormulaC7H4Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 40 Monomer (N-Nitroso Furosemide) structure
40
呋塞米杂质40 单体 (N-亚硝基呋塞米)Furosemide Impurity 40 Monomer (N-Nitroso Furosemide)
Furosemide Impurity 40 Monomer (N-Nitroso Furosemide)
CAS No.2708280-93-5
Chemical FormulaC12H10ClN3O6S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 41 structure
41
呋塞米杂质41Furosemide Impurity 41
Furosemide Impurity 41
CAS No.30170-04-8
Chemical FormulaC7H5F2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 43 structure
43
呋塞米杂质43Furosemide Impurity 43
Furosemide Impurity 43
CAS No.6660-65-7
Chemical FormulaC8H4Cl2O4
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 47 structure
47
呋塞米杂质47Furosemide Impurity 47
Furosemide Impurity 47
CAS No.2470439-95-1
Chemical FormulaC17H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 50 structure
50
呋塞米杂质50Furosemide Impurity 50
Furosemide Impurity 50
CAS No.4847-36-3
Chemical FormulaC8H7Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 53 structure
53
呋塞米杂质53Furosemide Impurity 53
Furosemide Impurity 53
CAS No.1860880-81-4
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 54 structure
54
呋塞米杂质54Furosemide Impurity 54
Furosemide Impurity 54
CAS No.2838431-70-0
Chemical FormulaC5H6ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 56 structure
56
呋塞米杂质56Furosemide Impurity 56
Furosemide Impurity 56
CAS No.4818-85-3
Chemical FormulaC12H12N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 57 structure
57
呋塞米杂质57Furosemide Impurity 57
Furosemide Impurity 57
CAS No.19377-82-3
Chemical FormulaC10H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 58 structure
58
呋塞米杂质58Furosemide Impurity 58
Furosemide Impurity 58
CAS No.4793-25-3
Chemical FormulaC9H9Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 60 structure
60
呋塞米杂质60Furosemide Impurity 60
Furosemide Impurity 60
CAS No.151104-67-5
Chemical FormulaC7H3Cl3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 62 structure
62
呋塞米杂质62Furosemide Impurity 62
Furosemide Impurity 62
CAS No.1870323-25-3
Chemical FormulaC7H5Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 63 structure
63
呋塞米杂质63Furosemide Impurity 63
Furosemide Impurity 63
CAS No.2905-61-5
Chemical FormulaC7H3Cl3O
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 64 structure
64
呋塞米杂质64Furosemide Impurity 64
Furosemide Impurity 64
CAS No.72290-28-9
Chemical FormulaC7H5Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 65 structure
65
呋塞米杂质65Furosemide Impurity 65
Furosemide Impurity 65
CAS No.869965-83-3
Chemical FormulaC7H5Cl2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 71 structure
71
呋塞米杂质71Furosemide Impurity 71
Furosemide Impurity 71
CAS No.1803102-41-1
Chemical FormulaC10H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 73 structure
73
呋塞米杂质73Furosemide Impurity 73
Furosemide Impurity 73
CAS No.16271-33-3
Chemical FormulaC6H3Cl3O2S
Purity>95%询价On request
10mg25mg50mg100mg
Furosemide Impurity 77 structure
77
呋塞米杂质77Furosemide Impurity 77
Furosemide Impurity 77
CAS No.116436-17-0
Chemical FormulaC15H15NO3
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

呋塞米 —— 研究文献与合成路线Furosemide — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 呋塞米 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Furosemide. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Implementation of design of experiments for optimization of forced degradation conditions and development of a stability-indicating method for furosemide
    Kurmi M, Kumar S, Singh B, et al. · Journal of pharmaceutical and biomedical analysis · 2014 · 被引 26cited 26
  2. Isolation and Characterization of an Unknown Process-Related Impurity in Furosemide and Validation of a New HPLC Method
    Xu A, Xue Y, Zeng Y, et al. · Molecules (Basel, Switzerland) · 2023 · 被引 6cited 6
  3. An Insight into the Degradation Processes of the Anti-Hypertensive Drug Furosemide
    Giannetti M, Canale VC, Micheli L, et al. · Molecules (Basel, Switzerland) · 2023 · 被引 3cited 3
  4. Reversed-phase ion-pair liquid chromatographic method for determining the impurities of furosemide
    Miller JH, Robert JL, Sørensen AM · Journal of pharmaceutical and biomedical analysis · 1993 · 被引 4cited 4
  5. The influence of intravenous furosemide on the renal excretion pattern of protein and protein degradation products
    Andreasen F, Hansen U, Husted SE, et al. · Acta pharmacologica et toxicologica · 1984 · 被引 3cited 3
  6. Furosemide ethanol-free oral solutions for paediatric use: formulation, HPLC method and stability study
    Zahálka L, Klovrzová S, Matysová L, et al. · European journal of hospital pharmacy : science and practice · 2018 · 被引 9cited 9

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF FUROSEMIDE
    SIGNOR ANGELO, GUERRATO ALFREDO, SIGNOR GIOVANNI · 公开号 EP0788494EP0788494 · 1997
  2. PROCESS FOR THE PREPARATION OF FUROSEMIDE
    SIGNOR ANGELO, GUERRATO ALFREDO, SIGNOR GIOVANNI · 公开号 WO9612714WO9612714 · 1996
  3. Ready for use, injectable, aqueous solutions of alkali metal salts of canrenoic acid and furosemide and process for their preparation
    LEEB RICHARD, HELBIG RAINER J · 公开号 US4301160US4301160 · 1981
  4. Directly injectable aqueous solutions of the alkali salts of canrenoic acid and of furosemide, and process for their production
    Leeb Richard Dr., Helbig Rainer Joachim · 公开号 EP0030681EP0030681 · 1981

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

呋塞米 杂质谱研究要点Furosemide — impurity profiling notes

下面这些是拿到 呋塞米 的 43 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 43 impurity entries for Furosemide, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances